TPST News and Press, Tempest Therapeutics Inc. From 11/20/25

A look at the top 10 most actives in the United States Autozi Internet Technology (Global) Ltd. (AZI) rose 12.0% to $0.085 on volume of 480,945,530 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 5.1% to $4.13 on volume of 355,767,751 shares Freight Technologies Inc. (FRGT) r...

A look at the top 10 most actives in the United States Autozi Internet Technology (Global) Ltd. (AZI) rose 14.5% to $0.0869 on volume of 455,993,718 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 4.7% to $4.145 on volume of 295,215,577 shares Freight Technologies Inc. (FRGT)...

All-stock acquisition includes clinical-stage CD19/BCMA Dual-CAR T program Acquisition will expand existing advanced clinical-stage pipeline of amezalpat (PPAR ⍺ Antagonist, Phase 3-ready) and TPST-1495 (Dual Ep2/4 Antagonist, Phase 2 start expected near term) The a...

2025-11-05 13:00:58 ET More on Tempest Therapeutics Tempest Therapeutics GAAP EPS of -$2.07 beats by $0.58 Seeking Alpha’s Quant Rating on Tempest Therapeutics Historical earnings data for Tempest Therapeutics Financial information for Tempest Therapeu...

BRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class 1 targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended September...

Tempest Therapeutics Inc. (TPST) is expected to report $-3.23 for Q2 2025

2025-08-11 16:45:32 ET More on Tempest Therapeutics Tempest announces $4.6 million registered direct offering of common stock; shares decline over 13% Tempest Therapeutics GAAP EPS of -$3.16 misses by $0.01 Seeking Alpha’s Quant Rating on Tempest Therapeutics ...

Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in China Granted orphan drug designation from the European Medicines Agency (EMA) for amezalpat for the treatment of patients with HCC Presented new amez...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Cancer is no longer just a disease of aging populations. Researchers are sounding the alarm over rising rates of early-onset cancer , with a National Cancer Institu...

Builds on clearances already received by FDA and EMA China has the largest population of patients with hepatocellular carcinoma in the world BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a...